Background: The ESHAP regimen, a combination of the chemotherapeutic drugs etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C) and cisplatin, has been shownto be active against refractory non-Hodgkin's lymphoma in therapeutic trials. We were interested in determining whether this regimen would be effective and tolerable for Chinese patients. Methods: Thirty-twopatients with refractory/relapsed non-Hodgkin's lymphoma (23intermediate-grade and nine high-grade) were enrolled in this study. Etoposide was administered at a dose of 40 mg/m 2/day as a 1 h intravenous infusion from day 1to day 4, solumedrol 500 mg/daywasgiven as a 15 min intravenous infusion from day 1 to day 5, ara-C2 g/m 2 was given as a 2 h intravenous infusion on day 5 and cisplatin was givenat a dose of 25 mg/m 2/day as a continuous infusion from day 1 to day 4. Clinical efficacy and toxicity were assessed on the basis of the WHO criteria. Results: Ten patients (31.3%, 95% CI15.2-47.4%) attainedcomplete remission (CR)and seven had partial remission (PR). The overall response rate was 53.1 % (95% CI 35.8-70.4%). In eight of the 10 CR patients, the remission lasted for more than 8 months. The remaining two patients had CR of 5 and 6 months. The median duration of CR was 12.2 months (range 5-22 months). Myelosuppression with subsequent infections was the major toxicity. Severe leukopenia (WBC <1 OOO/~.lI) lasted for an average of 12 days and thrombocytopenia «25 000/111) 18 days. One patient(3.1 %) diedof neutropenia-associated sepsiswithin 4 weeksaftertreatment. Non-myeloid toxicities included alopecia in 66% (28% grade 2,22% grade 3), stomatitis in 72% (25% grade 2,28% grade 3,13% grade4), hepatotoxicity in 9% (3% grade2), renal toxicityin 13% (6% grade 2,3 % grade 3) and infection in 56% (18% grade 2,25% grade 3,13% grade 4). The majorityof the responders relapsed within 2 years after ESHAP treatment. Median survival for all patients was 8.6 months. Conclusions: ESHAP is an activeandtolerable regimen in Chinese patients with relapsed/refractory lymphoma, but the duration of remission is brief and without significant impacton survival.
INTRODUCTION
Although the treatment of advanced diffuse non-Hodgkin's lymphoma (NHL) has improved considerably, long-term patient survival using the current therapies still remains less than 50% (1) . Despite a high initial response rate to therapy, relapse of lymphoma is usually associated with a poor prognosis, with a median survival ofless than 8 months (2). Salvage chemotherapy for such patients is indicated.
Numerous clinical trials for refractory lymphoma have shown results that are ultimately disappointing: the majority of patients failed to attain remission or only a brief remission was observed (3) . The use of high-dose chemotherapy with the support of autologous bone marrow stem cells (autologous bone marrow transplantation) to overcome such resistance has been proposed by some investigators (4) . Currently, high-dose chemotherapy with autologous bone marrow transplantation strategy has been applied mostly in a younger population, with good performance status and prior chemotherapy-sensitive disease (5, 6) . Thus, the majority of lymphoma patients who are old or with prior chemotherapy resistance are not considered as candidates for this approach.
RESULTS
CHOP, cyclophosphamide, adriamycin, oncovin, prednisolone; m-BACOD, methotrexate, bleomycin, adriamycin, cyclophosphamide, oncovin, dexamethasone; COPBLAM, cyclophosphamide, oncovin, prednisolone, bleomycin, adriamycin, procarbazine; OPDL, oncovin, prednisolone, daunorubicin, leunase.
Among the 32 eligible patients, one died of treatment-related toxicity (neutropenia-associated sepsis)and was categorized as a non-responder. Ten patients (31.3%, 95% CI 15.2-47.4%) attained CR and seven had PRo The overall response rate was 53.1% (95% CI 35.8-70.4%). In eight of the 10 CR patients, the remission lasted for more than 8 months. The other two patients had CR for 5 and 6 months, respectively. The median duration of CR was 12.2 months (range 5-22 months). The remaining 14 were non-responders. Median survival for all patients was 8.6 months.The overallsurvivalof all patientsis shownin Fig. 1 .The majority of the responders relapsed within 2 years after ESHAP treatment. In this study,subsequenthigh-dosechemotherapywith autologous blood stem cell transplantation was not performed in the responding patients because of poor performance status, old age or poor cardiac performance or pulmonary functions.
Treatment-related myelosuppression was found in all patients. Grade 4 neutropenia (neutrophils <500/1ll), grade 4 leukopenia (WBC <IOOO/J..lI) and thrombocytopenia (platelets <25000/J..lI) were found in all patients. Myelosuppression with subsequent infection was the major toxicity of this regimen. Severe leukopenia(WBC <1000/IlI) lasted for an averageof 12 days and 34 ESHAP for refractory NHL In 1994, the ESHAP regimen, an active combination of etoposide, methylprednisolone (solumedrol), high-dose cytarabine (ara-C) and cisplatin,in the treatmentof refractoryNHL was reported (7) . In that trial, 37% of the patients attained complete remission (CR) and in an additional 27% partial remission (PR) was also observed. In another trial using ESHAP as salvage therapy for 26 patients with relapsed/refractory lymphoma, 27% CR and 42% PR were observed without excessive toxicity (8) . Therefore, we were interested in determining whether this regimen would be effective and tolerable for Chinese patients. Here we report preliminary data on the efficacy and toxicity of ESHAP in 32 Chinese patients with refractoryor relapsed NHL.
PATIENTS AND METHODS
Between October 1995 and September 1997, 32 patients with advanced NHL, relapsed or refractory to conventionaltreatment, were considered eligible for this study. All had records of measurable biopsy-confirmed NHL, normal serum creatinine levels, normal or mildly-elevated serum transaminase levels (within 1.5 times the upper limit of normal range) and no active infection. Patients who were carriers of hepatitis virus B or C without active hepatitiswere allowedin this study.The classification of disease was based on the Working Formulation. All patients were required to have a performancestatus (PS) (Zubrod scale) of 2 or less and adequate hematopoietic function as evidenced by leukocyte counts >3000/lll and platelet count >100 OOO/Jll. All patients should have a life expectancy of more than 3 months and no other malignancies exceptlymphoma.Prior radiotherapy was allowed. All patients gave their written informed consent. Their characteristics are shown in Table 1 .
Etoposide was administered at a dose of 40 mg/m 2/day as a 1 h intravenous infusion from day 1 to day 4, solumedrol 500 mg/day was given as a 15 min intravenous infusion from day 1 to day 5, ara-C 2 g/m 2 was given as a 2 h intravenous infusionon day 5 and cisplatin was given at a dose of 25 mg/m-zday as a continuous infusion from day 1 to day 4. Granulocyte colony-stimulating factor (G-CSF) was administered at a dose of 300 ug/day by subcutaneous injectionwhenpatients' WBC was less than l000/1l1 for three consecutive days. Response was evaluated after the first courseof treatmentand toxicities wereevaluated aftereachcourse. CR was defmed as complete disappearance of all measurable diseasefor at least 4 weeks. PR was definedas >50% reduction in the sum of the product of the cross-sectional diameters of all measurable lesionsfor at least4 weeks. Non-responders (NR) were patientswith grosslyresidualor progressive disease. Treatment-related death was considered to have occurred when patients died within 4 weeks after the start of therapy.
Toxicities were assessed on the basis of the WHO criteria and graded from 0 to 4. Time of recoveryfrom myelosuppressionwas defined as the duration from the first day of treatment to the day when the white blood cell countexceeded 1000/J..lI and the platelet count exceeded 25 OOO/IlI without platelet transfusion. Curves relating patients' overall survivalconstructedusing the method of Kaplan and Meier (9). historical comparison, several differences were observed between ESHAP and DHAP. First, ESHAP regimen is associated with a longer survival and time-to-treatment failure (1TF) compared with DHAP. Second, although the ESHAP combination seemed superior to DHAP, neither of them is associated with a cured fraction of >10%. The majority of these patients had recurrence, except those who had bone marrow transplantationfor consolidation.The authors also found that only very few patients, irrespective of histological diagnosis, survived for more than 3 years (11). However, because of superior activity, milder myelosuppressive effect and better tolerance, the authors favor ESHAP instead of DHAP to be used in refractory/relapsed NHLs.
In contrast to the study conducted by Velasquez et al., in 1993 Johnson et al. (12) reported on 28 patients with refractory NHLs who received ESHAP. In that study, no objective responses were found although five patients had a transient reduction in tumor size. Median TTF was only 2.5 months and median survival was 7 months from the start of ESHAP. The authors considered that the reason why their results were markedly different to those reported by Velasquez et al. is possibly due to different patient selection. In Johnson et a1.'s study, 22 patients had previously been heavily treated with etoposide. However, the authors concluded that ESHAP shows strictly limited efficacy but marked toxicity in patients with refractory NHLs.
More recently, Rodriguez et a1. (13) introduced the MINE-ESHAP regimen, which consists of mesna, ifosphamide, mitoxantrone (novantrone) and etoposide up to maximum response, followed by ESHAP consolidation. In the authors' experience, this strategy was associated with a higher response rate and a superior failure-free survival compared with the ESHAP and DHAP. The overall and complete response rates of MINE-ESHAP were 69 and 48%, respectively. The median survival was 24 months and the median TTF was 12 months, which were much longer than with ESHAP and DHAP. However, the differences between MINE-ESHAP, ESHAP and DHAP were compared historically; a prospective, randomized study would be useful to determine which one is better. Furthermore, the follow-up of MINE-ESHAP was shorter and one cannot determine the exact proportion of patients cured by this treatment. thrombocytopenia «25 OOO/Jll) 18 days. One patient (3.1%) died of neutropenia-associated sepsis within 4 weeks after treatment. Non-hematological toxicities including nausea, vomiting, stomatitis, alopecia, skin rashes, chemical conjunctivitis, central nervous system toxicity and elevation of serum transaminase and creatinine levels are shown in Table 2 . Severe stomatitis (grade 3 or 4) was found in 13 patients. Mild to moderate skin rash was found in three patients. Mild elevation of the serum transaminase level was noted in three patients, one grade 2. Elevation of the serum creatinine level was noted in four patients, including two grade 2 and one grade 3. Alopecia was found in 21 patients, grade 2 and 3 being seen in the majority. Infection was found in 18 patients, eight with grade 3 and four with grade 4. Only one patient had transient chemical conjunctivitis, grade 2. No significant cardiac toxicity was found.
DISCUSSION
Conventional chemotherapy can cure 35-50% of all newly diagnosed intermediate-and high-grade NHLs. For those whose disease relapsed or was refractory to conventional treatment, salvage therapy is indicated. Although high-dose chemotherapy and bone marrow/stem cell transplantation have replaced standard-dose salvage regimens in patients younger than 60-65 years, there remain patients who, because of old age or other reasons, are not eligible for this approach. In addition, there is also a need for an effective standard-dose salvage regimen capable of inducing good-quality remissions before proceeding to high-dose chemotherapy with stem cell transplantation.
In 1988, Velasquez et al. (10) reported the preliminary results of a combination regimen DHAP (dexamethasone, high-dose ara-C and cisplatin) as salvage therapy for refractory/relapsed NHL. In their study, a total of 90 patents achieved an overall response rate of 55%, including 31% CR. In a second study reported in 1994 (7), the authors added etoposide to DHAP to form a new regimen ESHAP The dose of cytarabine in the ESHAP regimen was reduced to only one dose to accommodate etoposide. With long-term follow-up, by In addition to ESHAP and DHAP, many other clinical studies have applied high-dose ara-C to patients with refractory lymphoma and shown considerable efficacy. In 1990 Ho et al. (14) reported 31 patients with relapsed NHL who were treated with ara-C 3 g/m 2/day for two doses and mitoxantrone 10 mg/m 2/day also for two doses. CR was obtained in seven patients (23%,95% CI 8-37%) for a median of 7 months with tolerable toxicities. In contrast to the study conducted by Ho et aI., in 1997 Wang et al. (15) reported 16 Chinese patients with refractory NHL treated with high-dose ara-C and mitoxantrone. In their study, five out of 16 (31%) patients died of treatment-related complications. The authors suggested that the regimen was too toxic to be acceptable as salvage therapy for refractory Nlfl.. Wilson et aI. (16) reported a regimen containing no ara-C and demonstrated a considerable response with tolerable toxicity. They combined etoposide, prednisolone, vincristine, cyclophosphamide and doxorubicin (EPOCH) in 74 patients with relapsed lymphoma and attained a CR rate of 27% and a PR rate of 60%. In that study, the incidence of febrile neutropenia was only 17%. Comparing the data for these regimens, our study revealed a similar CR rate (31.3%) in these poor-risk NHL patients (Table 3) .
Therapeutic toxicities in our study were similar to those in other reported series (7, 8) . The major complication of ESHAP was myelosuppression. In our study, all patients experienced grade 4 leukopenia and thrombocytopenia and all of them received G-CSF to reduce the period of severe leukopenia. However, grade 4 leukopenia (WEC <lOGO/ill) still lasted for an average of 12 days and one patient(3%) died within 4 weeks owing to profound myelosuppression with sepsis. Non-hematological toxicities, including stomatitis, dermatitis, impaired liver and renal functions, central nervous 'system toxicity and chemical conjunctivitis, are generally reversible and not life-threatening.
In our study, the median survival for all patients was short compared with the study conducted by Velasquez et aI. (8.6 versus 14 months). The majority of the responders in our study relapsed within 2 years after starting ESHAP treatment with a median TTF of only 11.4 months. The reason why our patients had a poorer prognosis is possibly due to different patient selection. All our patients had intermediate-or high-grade NHLs. In Velasquez et aI.'s study, 34 out of 122 patients were diagnosed as having low-grade NHLs.
In summary, our findings suggest that ESHAP is an active and tolerable regimen for treating relapsed/refractory lymphoma, but the duration of remission is brief and without significant impact on survival. Further studies are required to determine the optimum regimens for treating refractory non-Hodgkin's lymphoma.
